Trial Profile

A Phase II/III study of SOLIRIS in children and adolescents with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 23 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eculizumab (Primary)
Indications Neuromyelitis optica
Focus Therapeutic Use
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

30 Jul 2020 According to an Alexion Pharmaceuticals media release, the company plans to initiate this Phase II/III study in children and adolescents with NMOSD in second-half 2020.
06 May 2020 According to an Alexion Pharmaceuticals media release, the company plans to initiate this Phase II/III study in children and adolescents with NMOSD in the mid-2020.
30 Jan 2020 According to an Alexion Pharmaceuticals media release, the company plans to initiate this Phase II/III study in children and adolescents with NMOSD in the first quarter of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com